Live News EQUITY L impact Jul 14, 2026, 12:18 PM UTC

VYGR Additional VY1706 (Alzheimer's anti-tau Gene therapy) preclinical data bode well for program/company; reiterate BUY, $12PT @ Canaccord

VYGR Additional VY1706 (Alzheimer's anti-tau Gene therapy) preclinical data bode well for program/company; reiterate BUY, $12PT @ Canaccord

SquawkNews Newsroom

VYGR Additional VY1706 (Alzheimer's anti-tau Gene therapy) preclinical data bode well for program/company; reiterate BUY, $12PT @ Canaccord